Insider Trading: Kevin Tang Picked up 508,474 Shares of La Jolla Pharmaceutical Company (LJPC); LMP Capital & Income Fund (SCD)’s Sentiment Is 1.75

The director of La Jolla Pharmaceutical Co, Kevin Tang, has just bought – 508,474 shares of the firm he’s leading – coming to a total purchase of $15.00 million USD (this based on avg. stock price of $29.5). In the last month, he also obtained 40,000 shares with a total value $1.20 million USD. Because it was a significant deal, it’s not likely to stay unnoticed one. Kevin Tang today owns 4.14 million shares or 16.19% of La Jolla Pharmaceutical Co’s market cap. This substantial purchase occurred on March 19, 2018 and was submitted with the Security and Exchange Commission. The public filing is on hand here.

LMP Capital and Income Fund Inc. is a closed ended balanced mutual fund launched and managed by Legg Mason Partners Fund Advisor, LLC. The company has market cap of $234.14 million. It is co-managed by Clearbridge Investments, LLC, Western Asset Management Company Limited, and Western Asset Management Company. It has a 7.54 P/E ratio. The fund invests in public equity and fixed income markets across the globe.

Since December 29, 2017, it had 4 insider purchases, and 1 insider sale for $8.26 million activity. PERCEPTIVE ADVISORS LLC had bought 175,000 shares worth $5.73 million. $1.20 million worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) was bought by TANG KEVIN C on Friday, March 2. 10,000 shares were sold by Douglass Laura L., worth $323,208 on Friday, December 29. CARVER JENNIFER also bought $32,475 worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares.

Among 8 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 5 have Buy rating, 3 Sell and 0 Hold. Therefore 63% are positive. La Jolla Pharmaceutical Company has $90.0 highest and $20.0 lowest target. $46.86’s average target is 62.09% above currents $28.91 stock price. La Jolla Pharmaceutical Company had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was downgraded by JP Morgan to “Underweight” on Friday, December 8. The firm has “Buy” rating by Jefferies given on Monday, July 24. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, January 30. On Friday, December 22 the stock rating was maintained by Cowen & Co with “Buy”. The rating was downgraded by J.P. Morgan on Friday, December 8 to “Sell”. The firm earned “Buy” rating on Thursday, August 31 by Jefferies. On Tuesday, September 8 the stock rating was maintained by Chardan Capital Markets with “Buy”. Lake Street initiated La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Tuesday, May 24 with “Buy” rating. The rating was maintained by Jefferies with “Buy” on Monday, June 12. The stock has “Underperform” rating by Jefferies on Monday, February 12.

The stock decreased 1.83% or $0.54 during the last trading session, reaching $28.91. About 707,770 shares traded or 15.12% up from the average. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since March 20, 2017 and is uptrending. It has outperformed by 111.95% the S&P500.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $739.18 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Analysts await La Jolla Pharmaceutical Company (NASDAQ:LJPC) to report earnings on April, 26. They expect $-1.46 EPS, down 15.87% or $0.20 from last year’s $-1.26 per share. After $-1.74 actual EPS reported by La Jolla Pharmaceutical Company for the previous quarter, Wall Street now forecasts -16.09% EPS growth.

Investors sentiment decreased to 1 in Q3 2017. Its down 0.61, from 1.61 in 2017Q2. It dropped, as 10 investors sold La Jolla Pharmaceutical Company shares while 21 reduced holdings. 25 funds opened positions while 25 raised stakes. 23.31 million shares or 1.99% less from 23.78 million shares in 2017Q2 were reported. Group Inc holds 11,721 shares or 0% of its portfolio. Goldman Sachs Grp has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Trexquant Inv Lp holds 6,230 shares. Quantitative Investment Mgmt Limited Liability Corporation accumulated 0.06% or 147,900 shares. Consonance Cap Mgmt Limited Partnership has 7.7% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 2.00M shares. Td Asset Mngmt holds 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 12,900 shares. Moreover, Blackrock has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The Massachusetts-based State Street has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Virtu Fincl Ltd reported 13,104 shares or 0% of all its holdings. Citigroup has 12,247 shares. Great West Life Assurance Co Can owns 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 2,654 shares. State Board Of Administration Of Florida Retirement reported 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Raymond James & Associates holds 0% or 44,076 shares. Bnp Paribas Arbitrage holds 1,736 shares or 0% of its portfolio. Perceptive Advisors Ltd Limited Liability Company accumulated 2.86% or 2.16 million shares.

The stock decreased 1.81% or $0.24 during the last trading session, reaching $13.02. About 71,304 shares traded or 3.02% up from the average. LMP Capital and Income Fund Inc. (SCD) has risen 13.90% since March 20, 2017 and is uptrending. It has underperformed by 2.80% the S&P500.

Cue Financial Group Inc. holds 0.38% of its portfolio in LMP Capital and Income Fund Inc. for 37,536 shares. Cornerstone Advisors Inc owns 156,931 shares or 0.26% of their US portfolio. Moreover, Rivernorth Capital Management Llc has 0.14% invested in the company for 122,016 shares. The Colorado-based Advisors Asset Management Inc. has invested 0.1% in the stock. Thomas J. Herzfeld Advisors Inc., a Florida-based fund reported 7,833 shares.

Since January 1, 0001, it had 0 buys, and 1 insider sale for $101,899 activity.